Introduction
Bladder cancer is the fifth most common cancer type, with an estimated 76 960 new cases and 16 390 deaths expected for 2016 in the United States alone [1] Up to 20% of patients have muscle invasion at diagnosis and 5% metastatic disease [2] . Metastatic urothelial cancer (UC) is chemosensitive; however, most patients who initially respond to multi-agent chemotherapy such as MVAC (methotrexate, vinblastine, gemcitabine, and cisplatin) or GC (gemcitabine or cisplatin), have a 5-year survival of only 5%-15% [3] [4] [5] .
Patients treated with multi-agent chemotherapy that have Karnofsky Performance Status <80% and visceral disease have the poorest prognosis with limited survival benefit from therapy [4] . Recently, immune checkpoint inhibitors have demonstrated significant antitumor effect, with superior survival benefit seen when compared with chemotherapy [6] , but this benefit is seen in only 20% of patients. In addition to immunotherapeutic strategies, exploring new targeted therapies might help to optimize treatment or to overcome de novo drug resistance.
Heat shock proteins as Hsp27 are overexpressed in UC tissue compared with normal urothelium, especially in high-grade tumors [7, 8] and are a family of highly conserved proteins induced by cell stressors (oxidative stress, cytotoxic chemotherapy, and radiation) . Hsp27 also stabilizes mutated or inappropriately activated oncoproteins in tumors, which can contribute to the growth and metastasis of human cancers [9] [10] [11] [12] [13] .
Apatorsen is an antisense oligonucleotide designed to bind to Hsp27 mRNA, inhibiting the production of Hsp27 protein. In vitro, apatorsen-sensitized several bladder cancer cell lines to gemcitabine or cisplatin and induced dose-dependent decreases in cell growth. In preclinical studies, apatorsen inhibited bladder tumor growth in mice, enhanced sensitivity to paclitaxel, and induced significantly higher levels of apoptosis compared with control mice [14] . These features suggest that apatorsen may provide a novel treatment of bladder cancer and potentially help address resistance to chemotherapeutic agents. In several early clinical studies, apatorsen was generally well tolerated and showed signs of clinical benefit in patients with prostate or bladder cancer [15] [16] [17] [18] .
We conducted a double-blind, placebo-controlled, randomized study to evaluate whether apatorsen in combination with standard gemcitabine plus cisplatin first-line chemotherapy could improve survival in patients with metastatic or locally advanced inoperable UC, compared with gemcitabine plus cisplatin with placebo.
Materials and methods

Study design and patients
Eligible patients had documented metastatic or locally advanced (T4b, N2, N3) inoperable UC of the urinary tract and were not candidates for curative surgery or radiotherapy. UC histology >50% was required for mixed histologies, and the presence of any small cell component was an exclusion criteria. Measurable disease was required according to RECIST 1.1 [19] . Patients should not have received any prior systemic chemotherapy, except neoadjuvant/adjuvant systemic chemotherapy given at least 12 months before enrollment. Secondary malignancy requiring therapy (except non-melanomatous skin cancer), as well as those with brain metastases or carcinomatous meningitis, were excluded. Other key eligibility criteria included: adequate baseline organ function; Karnofsky Performance Status !70%; absolute neutrophil count !1.5 Â 10 9 cells/l; and platelet count !125 Â 10 9 /l and calculated creatinine clearance ! 60 ml/min (Cockcroft-Gault formula) [20] .
This was a double-blind, placebo-controlled, phase II trial with 183 patients randomized at 50 sites in the United States, Canada, and Europe (ClinicalTrials.gov NCT01454089). The study was approved by institutional review boards at every site, and written informed consent was obtained from all patients.
All patients received three separate loading i.v. doses every other day of placebo (placebo arm) or 600-1000 mg apatorsen followed by up to six 21-day cycles of GC plus weekly placebo or apatorsen at the two established dose levels. Patients who received at least four cycles of chemotherapy and without documented disease progression were allowed to receive weekly study drug/placebo maintenance until disease progression or unacceptable toxicity.
Randomization and masking
Patients were randomly assigned (1:1:1) after stratification by the presence or absence of visceral disease (liver, lung, or bone metastases) and by Karnofsky Performance Status score (!80% versus <80%). Patients, study investigators, and the Sponsor were masked to treatment assignment. At each site, access to the treatment code was limited to unblinded pharmacists (or qualified designees).
Procedures
Patients were followed up every 6 weeks until disease progression or earlier, if clinically indicated, using computed tomography (CT) of the chest, abdomen, and pelvis. Magnetic resonance imaging was acceptable if it was consistently used for disease assessments. A bone scan was required at baseline. RECIST 1.1 was used to assess disease response. Survival follow-up data were collected every 3 months.
National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, was used for toxicity assessment. Samples for exploratory pharmacokinetic and pharmacodynamic studies, including circulating tumor cells (CTC), plasma apatorsen trough and C max levels, serum Hsp27 (sHsp27) levels (using enzyme-linked immunosorbent assay analysis), were analyzed by a central laboratory. Serum Hsp27 samples were collected at screening, before the first loading dose, every 3 weeks during treatment, and during each off treatment follow-up visit.
Laboratory values and physical signs were evaluated on days 1 and 8 of each cycle to assess if dose modifications (reductions or delays) were necessary. In general, weekly study drug administration would continue if a chemotherapy cycle was delayed due to toxicity. A delay in dosing of >4 weeks or >2 dose reductions required discontinuation from all study treatments. See supplementary Appendix S1, available at Annals of Oncology online, for Criteria for Dose Reduction.
Outcomes
The primary objective was overall survival (OS) relative to the placebo arm for three comparisons: 600 mg apatorsen versus placebo; 1000 mg apatorsen versus placebo; and pooled 600 and 1000 mg apatorsen versus placebo. Survival was calculated from the date of randomization to the date of death from any cause. Secondary efficacy end points were overall response rate (confirmed CR, confirmed PR), disease control rate (PR, CR, or stable disease), duration of overall response, and progression-free survival (PFS), defined as the time from randomization to the date of disease progression or death, whichever came first. For patients who remained alive without progression, PFS was censored on the date of the last tumor assessment. Pharmacodynamic end points included sHsp27 levels and CTC counts. Pharmacokinetic end points included C max and trough levels of apatorsen at each cycle of treatment.
Statistical analysis
The primary efficacy analysis was carried out on the full analysis set, which included all randomized patients who received at least one dose of study drug (intent to treat). Each comparison had 80% power to detect a survival benefit using the one-sided 0.05 level of a stratified log-rank test with a hazard ratio (HR) of 0.5.Associations between survival outcome and sHsp27 levels were assessed using baseline levels and change in sHsp27 levels as a normalized area under the curve (AUC) calculation for the first 100 days during study treatment. A landmark evaluation for survival outcomes using sHsp27 AUC values through day 100 of study treatment was carried out.
Multivariate statistical modeling of prognostic factors in placebo-arm patients was used to identify variables confirmed in other external studies [4, 21] as having prognostic value for survival. Contributory prognostic variables were identified by the modeling, and coefficients were used to compute a survival statistical model score (SMS) for each patient. For each comparison, patients with an SMS above or below the pooled median were classified as having good or poor prognosis, respectively.
Results
Between 24 November 2011 and 24 July 2013, 256 patients were screened and 183 patients were randomized to (i) GC plus placebo (N ¼ 62), (ii) apatorsen 600 mg (N¼ 60), or (iii) apatorsen 1000 mg (N ¼ 61). All patients had discontinued treatment as of 28 August 2014, and the data cutoff for primary analysis was 11 November 2014. Four of the randomized patients did not receive study treatment and were not included in the full analysis set ( Figure 1 ). Baseline characteristics including visceral disease were well balanced between treatment arms (Table 1) . Entered maintenan period
Median cycles of chemotherapy were 6 in the placebo arm, 6 in the 600-mg apatorsen arm, and 5 in the 1000-mg apatorsen arm. The main reason for treatment discontinuation was progressive disease in all arms [placebo 43/61 (70%), 600 mg apatorsen 27/58 (47%), 1000 mg apatorsen 23/60 (38%)]. Treatment discontinuation due to an adverse event (AE) was highest in the apatorsen 1000-mg arm [23/60 (38%)] and in the apatorsen 600-mg arm [13/58 (22%)] compared with the placebo arm [2/61 (3%)]. Other reasons for treatment discontinuation are summarized in supplementary Table S1 , available at Annals of Oncology online.
Efficacy
Survival was not significantly improved in either apatorsen arm versus the placebo arm. Median survival for patients in the placebo arm was 15.0 months [95% confidence interval (CI), 11.7-19.4)] versus 15.3 months (95% CI, 10.7-23.2) and 15.6 months (95% CI, 11.5-19.2) for patients in the 600-and 1000-mg apatorsen treatment arms, respectively. Relative to the placebo arm, HRs were 0.86 (95% CI, 0.54-1.36; P ¼ 0.252) and 0.90 (95% CI, 0.57-1.41; P ¼ 0.320), respectively ( Table 2) . Kaplan-Meier estimates are shown in Figure 2 .
Overall response rates were comparable among the three treatment arms, with median duration of response being slightly longer in the 600-and 1000-mg apatorsen arms (8.5 months; 95% CI, 4.6-11.7 and 7.2 months; 95% CI, 5.1-11.2, respectively) versus the placebo arm (5.1 months; 95% CI, 3.7-8.3). Analyses of other secondary efficacy end points are summarized in Table 2 .
A total of 55 placebo-arm patients with complete baseline data were included in post hoc statistical modeling. The following variables were identified as being associated with poor prognosis: Karnofsky Performance Status 80%, liver involvement, low hemoglobin, and high alkaline phosphatase levels. These prognostic variables were used to compute the SMS in the placebo arm and to classify patients as having poor (N ¼ 32; median survival, 9 months) versus good (N ¼ 23; median survival, 21.9 months) prognosis (estimated HR, 3.46; P ¼ 0.0005). No difference because the specific dichotomization was found compared with established Bajorin's prognostic factors [4] . The SMS score computed for patients with complete baseline data in the 600-and 1000-mg apatorsen arms also showed similar partitioning between poor and good prognosis.
For OS, the HR in the poor risk patients was of 0.72 for the apatorsen 600-mg arm compared with placebo arm and of 1.45 in the good prognosis with no benefit seen in the 1000-mg apatorsen arm (less median number of cycles and more frequent treatment discontinuation due to AE in this treatment arm). Median PFS was also slightly improved in poor-prognosis patients treated with 600 mg apatorsen (5.6 months; HR ¼ 0.78) versus poor-prognosis patients in the placebo arm (4.6 months) but not with 1000 mg apatorsen (3.6 months; HR ¼ 1.10). There was no difference in overall response rates between the arms (Table 3) . 
Correlation of biological markers with survival
In addition to the poor-prognostic features identified above, baseline levels of sHsp27 and CTC counts were analyzed as possible prognostic variables in association with OS. Survival was analyzed in dichotomized patient subgroups using values above and below the medians at baseline. Patient with higher baseline sHsp26 split at 6.95 ng/ml median had significanlty worse survival (HR ¼ 2.07, p ¼ 0.0002) (see Kaplan-Meier in Figure 3A) . Among the patients characterized as poor prognosis, baseline levels of sHsp27 were higher than in the good-prognosis subgroup ( Figure 3B ). Regarding CTC counts, OS in patients with >0 cells/ 7.5 ml CTC count values had was worse compared with patients with zero counts ( Figure 3C : HR ¼ 1.58, P ¼ 0.0002) and poor prognosis patients also had a higher mean CTC count ( Figure 3D ). Exploratory landmark analysis of study day 100 AUC sHsp27 levels showed a trend toward a survival benefit for apatorsen treatment (600 mg, 1000 mg, or both arms combined) in poorprognosis patients who achieved lower day 100 AUC sHsp27 levels compared with patients in the placebo arm (HR ¼ 0.45; 95% CI, 0.16-1.26; HR ¼ 0.62; 95% CI, 0.23-1.60; and HR ¼ 0.57; 95% CI, 0.23-1.39, respectively). A similar trend for apatorsen treatment was not observed for the poor-prognosis patients with higher day 100 AUC sHsp27 levels, or for good-prognosis patients, irrespective of day 100 AUC sHsp27 levels (supplementary Table S2 , available at Annals of Oncology online).
Safety
Among all treatment-emergent AEs, pyrexia, peripheral edema, abdominal pain, peripheral neuropathy, and chills appeared to be more common in both apatorsen-treatment arms and the placebo arm, while back pain and hematuria appeared to be most common in the 1000-mg apatorsen arm. A slightly higher proportion of patients in the 1000-mg apatorsen arm experienced dose reductions due to toxicities versus the other two arms (all nonhematological). Hematological and nonhematological adverse events are summarized in supplementary Tables S3-S9,  available (0) 44 (0) 45 (1) 50(1) 54 (1) 52 (0) 46 (1) 39 (1) 35 (0) 36 (1) 32 (1) 30 (0) 30 (1) 29 (1) 21 (5) 20 (5) 25 (4) 14 (9) 11 (13) 19 (10) 9 (12) 7 (16) 8 (17) 2 (19) 5 (18) 2 (22) 0 (20) 1 (22) 0 (24) 0 (20) 0 (23) 0 (24) 58(0) 60 ( Efficacy results in good-prognosis patients not shown; median survival hazard ratio (HR) for 600 mg apatorsen versus placebo, HR ¼ 1.45; for 1000 mg apatorsen versus placebo, HR ¼ 1.07. (1) 75 (1) 66 (1) 59 (1) 56 (1) 42 (9) 28 (21) 16 (29) 5(39) 0(44) 0 (44) 88 (0) 78 (0) 67 (1) 59 (1) 42 (1) 31 (1) 22 (5) 14 (11) 7 (15) 4 (18) 1 ( (1) 75 (1) 66 (1) 59 (1) 56 (1) 42 (9) 28 (21) 16 (29) 5(39) 0(44) 0 (44) 88 (0) 78 (0) 67 (1) 59 (1) 42 (1) 31 (1) 22 (5) 14 (11) 7 (15) 4 (18) 1 ( Pharmacokinetics Day 1 C max was increased between the 600-and 1000-mg apatorsen arms in a dose-dependent manner in all cycles and appeared to be similar across the six cycles, indicating no accumulation due to repeated dosing (supplementary Table S10 , available at Annals of Oncology online). The mean day 1 C max for apatorsen in this study appeared to be comparable with those from a previous study [17] .
Discussion
In this study, we assessed the ability of apatorsen in combination with chemotherapy to improve OS in the first-line advanced UC. Adding apatorsen at doses of 600 or 1000 mg to the first-line gemcitabine plus platinum chemotherapy in the global unselected population, the study failed in its primary end point and did not show a survival improvement (HR ¼ 0.86 and 0.90, respectively). Similarly, secondary efficacy end points, including PFS, as well as objective and overall response rates, were not different between the arms. However, and as hypothesis-generating finding, the study showed in a post hoc analysis using statistical modeling to identify patients with poor or good prognosis a trend toward improved survival in the poor-prognosis group in the 600-mg apatorsen arm versus placebo arm (HR ¼ 0.72).
Interesting biomarker findings were seen. When evaluating levels of sHsp27 as a potential prognostic biomarker and for on-target apatorsen effects as a predictive or pharmacodynamic biomarker, higher baseline sHsp27 levels predicted worse OS (HR ¼ 2.01; P ¼ 0.0004). Patients characterized as poor prognosis had significantly higher baseline sHsp27 levels than patients characterized as good prognosis (P ¼ 0.0008). Landmark analysis of sHsp27 levels demonstrated a trend toward a survival benefit with apatorsen treatment in patients with poor prognosis who achieved lower day 100 AUC sHsp27 levels on study treatment. In these poor prognosis patients, a survival benefit was observed in both the 600-and 1000-mg apatorsen arms (HR ¼ 0.45 and 0.62) and in the pooled apatorsen arm (HR ¼ 0.57) versus poor prognosis patients in the placebo arm. These results suggest that inhibition of Hsp27 may impact the intrinsic biology of patients who have poor risk factors. In addition, in the patients characterized as poor prognosis, higher baseline CTC counts (!5 cells/ 7.5 ml) were observed compared with patients with good prognosis. This finding did correlate with poor survival.
In general, toxicity was greater in the 1000-mg apatorsen arm than in the apatorsen 600 mg or placebo arms with patients discontinuing treatment at a higher rate, which appeared to be dose dependent. The higher rate of discontinuation and higher proportion of patients requiring dose reductions in the 1000-mg apatorsen arm reduced overall exposure to chemotherapy as well as apatorsen when compared with patients in the placebo and 600-mg apatorsen arms. This difference in amount of therapy received may potentially explain the reduction in apparent antitumor activity with the 1000 mg apatorsen dose. Treatment-emergent AEs ! grade 3 that appeared to be more common in one or both apatorsen-treatment arms versus the placebo arm were nonlaboratory AEs of urinary tract infection, hypertension, and back pain, as well as laboratory AEs of cytopenias and hyponatremia. Patients in this phase II study were premedicated with an antihistamine, H2 antagonist, and corticosteroid before each loading dose and during cycle 1 of chemotherapy, at a minimum to prevent infusion reactions. This prophylaxis (with ibuprofen or acetaminophen) [17] appeared successful in decreasing the incidence of infusion reactions from 67% to 19% of patients in the 600-mg apatorsen arm and to 30% of patients in the 1000-mg apatorsen arm.
The present trial was a negative trial as per trial design, but several findings of this study shed light on the importance of patient selection driven by clinical or biological markers in advanced bladder cancer. Despite most of the conclusions being based on subgroup analyses, which have low statistical power, post-hoc analyses identified a subgroup of patients who appeared to have benefited from combination treatment with apatorsen and chemotherapy. Specifically, patients with poor prognosis seemed to benefit from combination treatment versus chemotherapy alone. These patients would be expected to be the most drug resistant. Consistent with this hypothesis is that high baseline sHsp27 levels were found to be prognostic, with higher baseline levels in the poor-prognosis subgroup compared with the goodprognosis subgroup. Since the poor-prognosis patients who achieved lower Hsp27 AUC levels during the first 100 days of treatment appeared to benefit more in both the 600 and 1000-mg arms, sHsp27 levels should be explored in future trials as a potential biomarker to predict response to apatorsen treatment.
The underlying biological explanation for apatorsen being of potential benefit in poor-prognosis patients could be explained by Hsp27 itself as a prognostic factor. In fact, in a recently presented second-line study combining apatorsen with docetaxel showed significantly improved OS compared with docetaxel alone (HR, 0.80; 80% CI, 0.65-0.98, one-sided P ¼ 0.0784, median OS 6.4 versus 5.9 months) although PFS and ORR were similar. In this trial, patients with low baseline Hsp27 levels had also a longer OS than those with higher levels regardless of treatment arm suggesting its prognostic value [22] .
In conclusion, further evaluation of apatorsen is warranted to assess clinical benefit in patients who have urothelial tumors and poor-prognostic features. As clinical trials remain ongoing to investigate immune-checkpoint inhibitors in first line "fit" or "unfit" patients DANUBE (NCT02516241) KEYNOTE-361 (NCT02853305) IMvigor 130 (NCT02807636), the role of apatorsen, if any,will be restricted to a highly accurate biomarker selected population that is not suitable for IO. Additional studies will be required to support the evidence that sHsp27 is a potential prognostic and/or predictive biomarker of response to apatorsen treatment.
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